Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

Phase 1/2 Active not recruiting 204 enrolled Orion Corporation, Orion Pharma

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer.

Timeline

Start: 2018-03-19
Primary completion: 2026-07-31
Completion: 2026-07-31

Publications

Fizazi K, Bernard-Tessier A, Roubaud G, Utriainen T, Barthelemy P, Flechon A, van der Voet J, Gravis G, Ratta R, Jones R, Parikh O, Tanner M, Antonarakis ES, Baldini C, Peters N, Garratt C, Ikonen T, Pohjanjousi P, Joensuu H, Cook N. Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer. NEJM Evid. 2024 Jan;3(1):EVIDoa2300171. doi: 10.1056/EVIDoa2300171. Epub 2023 Dec 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Midazolam	Small molecule	—	Oral
Subject	Opevesostat	Small molecule	5 mg	Oral

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications